耐多药或利福平耐药结核暴露者的管理
本文综述了接触传染性耐多药或利福平耐药结核患者的个体管理,涵盖基线评估、可能的预防性治疗、随访及共享决策。文章讨论了现有证据、不同管理策略的依据,以及与HIV或营养不良等继发合并症的交互影响。
要点
- 接触传染性MDR-RR结核者存在发病风险
- 高质量研究已提供预防性治疗选项
- 管理应包括基线评估、预防治疗、随访和共享决策
核心结论
- 针对MDR-RR结核暴露者的预防性治疗已有高质量研究证据支持。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 接触传染性MDR-RR结核的个体有发病风险。
- 已发表多项高质量研究详述高危接触者的预防治疗选择。
临床怎么用
- 应全面管理MDR-RR结核暴露者,包括基线评估、预防治疗、随访和共享决策。
- 需考虑HIV或营养不良等合并症的影响。
局限性
- 原文未明确报告综述的检索范围等局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Individuals exposed to a person with infectious multidrug-resistant or rifampicin-resistant (MDR-RR) tuberculosis are at risk of developing tuberculosis disease. Historically, insufficient empirical evidence for preventive treatment in this group has permitted inadequate guidance for clinical decision making. However, several high-quality studies have been published detailing preventive treatment options for these contacts at high risk. In this Review, we discuss the management of individuals exposed to patients with infectious MDR-RR tuberculosis. We pay particular attention to the entire spectrum of clinical care for this population, including baseline assessment, possible preventive treatments, follow-up, and shared decision making. We discuss the available evidence, the rationales for different management strategies, and the interactions with (and implications of) secondary comorbidities such as HIV or malnutrition.
引用
- Seddon JA, Achar J, Malik AA, et al. Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis. Lancet Infect Dis. 2025. PMID: 41036784. doi:10.1016/S1473-3099(25)00157-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。